2019
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research 2019, 21: 72. PMID: 31196152, PMCID: PMC6567382, DOI: 10.1186/s13058-019-1156-6.Peer-Reviewed Original ResearchConceptsPD-L1 expressionImmune cell PD-L1 expressionLung cancerImmune cellsTriple-negative breast cancerEasy scoring methodCompanion diagnostic testsPD-L1Immune therapyBreast cancerImmunohistochemical testsBetter outcomesLarger studyTumor cellsDiagnostic testsCancerExpression findingsCellsExpressionPoor agreementScoring methodTherapyTrials
2006
Molecular Classification of Breast Cancer: Limitations and Potential
Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular Classification of Breast Cancer: Limitations and Potential. The Oncologist 2006, 11: 868-877. PMID: 16951390, DOI: 10.1634/theoncologist.11-8-868.Peer-Reviewed Original ResearchConceptsBreast cancerMolecular classificationNovel risk stratification methodsEstrogen receptor immunohistochemistryBreast cancer patientsRisk stratification methodsRoutine diagnostic workupTranscription-polymerase chain reactionNew molecular classificationReceptor immunohistochemistryCancer patientsDiagnostic workupPolymerase chain reactionBest therapyMolecular subsetsPredictive valueClinical researchCancerDiagnostic testsPredictive testChain reactionMedical decisions
2005
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 8315-8320. PMID: 15914550, PMCID: PMC1149405, DOI: 10.1073/pnas.0408974102.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancerBreast cancer cellsLow tau expressionPaclitaxel-containing chemotherapyCancer cellsLower mRNA expressionRegulation of tauPaclitaxel therapyComplete responseIndependent predictorsNuclear gradePaclitaxel sensitivityTau expressionTherapeutic strategiesStage IMultivariate analysisProtein tauTau proteinMRNA expressionTissue arraysDiagnostic testsPaclitaxelCancerChemotherapy
2004
Improving patient care through molecular diagnostics
Perez EA, Pusztai L, van De Vijver M. Improving patient care through molecular diagnostics. Seminars In Oncology 2004, 31: 14-20. PMID: 15490370, DOI: 10.1053/j.seminoncol.2004.07.017.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsDihydrouracil Dehydrogenase (NADP)Gene Expression ProfilingGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesOligonucleotide Array Sequence AnalysisProteomicsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionThymidine PhosphorylaseConceptsLymph node statusPresence of metastasesSpecific tumor subtypesSingle tumor markerAdverse eventsMolecular diagnosticsNode statusSpecific therapyBreast cancerEstrogen receptorHistologic appearanceTumor gradingTumor markersTumor subtypesPatient careDiagnostic testsInitial evaluationParticular molecular defectsPatientsTherapyCancerParticular treatmentTreatmentSimultaneous assessmentDiagnostic techniques